BYSI Archives - Page 2 of 2

Developments

BeyondSpring prices $35-million equity offering

BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...

July 17, 2019

Developments

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...

May 21, 2019

Developments

Abstracts for BeyondSpring Plinabulin-Neulasta combination accepted at ASCO

Two of BeyondSpring’s (NASDAQ:BYSI) abstracts about its lead asset, Plinabulin, were accepted for publication in the proceedings of this year’s ASCO annual meeting May 31 to June 4 in Chicago. The data, derived from...

May 16, 2019

Developments

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

BeyondSpring (NASDAQ: BYSI) will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) annual meeting in...

March 25, 2019

Developments

BeyondSpring presents promising CIN data at ASCO-SITC clinical immuno-oncology symposium

BeyondSpring (NASDAQ:BYSI) presented new clinical results from its Study 106 program in the prevention of chemotherapy-induced neutropenia (CIN) for its lead asset Plinabulin at the 2019 ASCO-SITC clinical immuno...

March 5, 2019

Feature

BeyondSpring readies NDA filings for Plinabulin in U.S. and China

BeyondSpring (NASDAQ:BYSI) is preparing to file NDAs with the China FDA during the next six months for its lead asset, first-in-class agent Plinabulin, for the treatment of non-small cell lung cancer (NSCLC) and...

January 8, 2019

Tag - BYSI

BeyondSpring prices $35-million equity offering

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

Abstracts for BeyondSpring Plinabulin-Neulasta combination accepted at ASCO

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

BeyondSpring presents promising CIN data at ASCO-SITC clinical immuno-oncology symposium

BeyondSpring readies NDA filings for Plinabulin in U.S. and China

General

More